Riociguat for the treatment of chronic thromboembolic pulmonary hypertension

Hossein Ardeschir Ghofrani, Andrea M. D'Armini, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Eckhard Mayer, Gerald Simonneau, Martin R. Wilkins, Arno Fritsch, Dieter Neuser, Gerrit Weimann, Chen Wang

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety. RESULTS: By week 16, the 6-minute walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P-5in the riociguat group and increased by 23 dyn · sec · cm-5in the placebo group (least-squares mean difference, -246 dyn · sec · cm-5; 95% CI, -303 to -190; P

Original languageEnglish
Pages (from-to)319-329
Number of pages11
JournalNew England Journal of Medicine
Issue number4
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Riociguat for the treatment of chronic thromboembolic pulmonary hypertension'. Together they form a unique fingerprint.

Cite this